Advertisement

Are we really tackling the "evidence-based medicine issue" in Alzheimer's disease?

      Age-related medical conditions are increasingly becoming a research priority given the relevant burden for healthcare systems and the projected demographic changes occurring in our societies. Accordingly, several randomized controlled trials (RCTs) have being conducted in order to identify pharmacological and non-pharmacological interventions aimed at tackling their clinical manifestations and/or positively affecting their natural history. Besides testing the efficacy of interventions, RCTs should also provide a minimal core of key information allowing the results translation into the routine clinical practice. In other words, readers should be allowed to understand the potential generalizability of the findings to different settings and individuals (i.e., external validity) [
      • Rothwell P.M.
      External validity of randomised controlled trials: “to whom do the results of this trial apply?”.
      ]. Such necessity is often particularly under pursued when older people are recruited, being challenging to properly capture and describe the main characteristics of such population (e.g., frailty, comorbidities, polypharmacy) [
      • McMurdo M.E.T.
      • Witham M.D.
      • Gillespie N.D.
      Including older people in clinical research.
      ]. This has likely contributed to a repeatedly documented lack of fit between elderly participants in clinical trials and healthcare users [
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rothwell P.M.
        External validity of randomised controlled trials: “to whom do the results of this trial apply?”.
        Lancet. 2005; 365: 82-93
        • McMurdo M.E.T.
        • Witham M.D.
        • Gillespie N.D.
        Including older people in clinical research.
        BMJ. 2005; 331: 1036-1037
      1. Geriatrics. 1994; E7
        • Leinonen A.
        • Koponen M.
        • Hartikainen S.
        Systematic review: representativeness of participants in RCTs of acetylcholinesterase inhibitors.
        PLoS One. 2015; 10e0124500
        • Schoenmaker N.
        • Van Gool W.A.
        The age gap between patients in clinical studies and in the general population: a pitfall for dementia research.
        Lancet Neurol. 2004; 3: 627-630
        • Hebert L.E.
        • Weuve J.
        • Scherr P.A.
        • Evans D.A.
        Alzheimer disease in the United States (2010–2050) estimated using the 2010 census.
        Neurology. 2013; 80: 1778-1783
        • Canevelli M.
        • Adali N.
        • Cantet C.
        • Andrieu S.
        • Bruno G.
        • Cesari M.
        • et al.
        Impact of behavioral subsyndromes on cognitive decline in Alzheimer's disease: data from the ICTUS study.
        J Neurol. 2013; 260: 1859-1865